Abstract
The percutaneous treatment of coronary bifurcation lesions with stent implantation is associated with increased adverse clinical events and inferior angiographic outcomes, when compared with mid-vessel lesions. The Axxess stent is a dedicated, self-expanding, drug-eluting (Biolimus A9) bifurcation
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
